Physician profile
Deng Pan
NPI 1689257685
$1,538.26
in general payments reported to CMS, 2019-2025
11 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $40.52 · 2024: $558 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,538.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rti Surgical, INC | $492.17 | 2024-2025 | |
| Integra Lifesciences Corporation | $280.22 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Aroa Biosurgery Incorporated | $200.90 | 2025 | |
| Davol INC. | $155.00 | 2024 | Phasix Mesh |
| Acera Surgical, INC. | $134.62 | 2025 | Restrata Wound Matrix |
| Polynovo North America LLC | $87.01 | 2025 | Novosorb Btm |
| Solventum Corporation | $81.83 | 2024 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Kerecis Limited | $41.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Stryker Corporation | $24.02 | 2025 | Na, Medpor Titan |
| Takeda Pharmaceuticals U.S.A., INC. | $23.43 | 2023 | Gattex |
| Elite Orthopedics, LLC | $17.09 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deng Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.